Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile

American Journal of Cardiology

Volumn 90, Issue 6, 2002, Pages 628-630

  Kereiakes, Dean J ^a   Lincoff, A Michael ^b   Anderson, Keaven M ^c   Achenbach, Robert ^c   Patel, Kamlesh ^c   Barnathan, Elliot ^c   Califf, Robert M ^d   Topol, Eric J ^b  

^a Ohio Heart and Vascular Center   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c CENTOCOR INC   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; CREATINE KINASE; CREATINE KINASE MB; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; PLACEBO; PROTEIN INHIBITOR;

ADULT; AGE; AGED; ALGORITHM; ANALYSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY BYPASS SURGERY; CREATINE KINASE BLOOD LEVEL; DEATH; DEMOGRAPHY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GENDER; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; REVASCULARIZATION; RISK ASSESSMENT; SMOKING; STENT; SURVIVAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOGENESIS; WEIGHT;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037106984     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02568-7     Document Type: Article

References (11)

1. Neumann F.J., Gawaz M., Ott I., May A., Mossmer G., Schomig A. Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting. J Am Coll Cardiol. 27:1996;15-21.
2. Tshoepe D., Schultheiss H.P., Kolarov P., Schwippert B., Dannehl K., Nieuwenhuis H.K., Kehrel B., Strauer B., Gries F.A. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation. 88:1993;37-42.
3. The EPIC Investigators . Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med. 330:1994;956-961.
4. The IMPACT-II Investigators . Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention IMPACT-II . Lancet. 349:1997;1422-1428.
5. RESTORE Investigators . Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 96:1997;1445-1453.
6. ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial. Lancet 2000;356:2037-2044.
7. The EPILOG Investigators . Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 336:1997;1689-1696.
8. Lincoff A.M., Califf R.M., Moliterno D.J., Ellis S.G., Ducas J., Kramer J.H., Kleiman N.S., Cohen E.A., Booth J.E., Sapp S.K., Cabot C.F., Topol E.J., Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators . Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med. 341:1999;319-327.
9. Anderson K.M., Califf R.M., Stone G.W., Neumann F.J., Montalescot G., Miller D.P., Fergusson J.J., Willerson J.T., Weisman H.F., Topol E.J. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol. 37:2001;2059-2065.
10. Kereiakes DJ, Obenchain RL, Barber BL, Smith A, McDonald M, Broderick TM, Runyon JP, Shimshak TM, Schneider JF, Hattemer CR, et al. Abciximab provides cost-effective survival advantage in high-volume interventional practice. Am Heart J 2000;140:603-610.
11. Topol EJ, Lincoff AM, Kereiakes DJ, Kleiman NA, Cohen EA, Ferguson JJ, Tcheng JE, Anderson KM, Barnathan ES, Califf RM, for the EPIC, EPILOG, and EPISTENT Investigators. Multi-year follow-up of abciximab therapy in three randomized controlled trials of percutaneous coronary revascularization. Am J Med 2002;113:1-6.